


Supplemental Digital Content

Mistry PK, et al. Acid Sphingomyelinase Deficiency and Gaucher Disease: Underdiagnosed and Often Treatable Causes of Hepatomegaly, Splenomegaly, and Low HDL Cholesterol in Lean Individuals

SDC Figure 1. HDL cholesterol over time in the ASCEND trial of olipudase alfa treatment for acid sphingomyelinase deficiency (ASMD)¹ and the ENGAGE trial of eliglustat treatment for Gaucher disease type 1 (GD1)²



*Baseline values for original placebo patients refer to day 1 of the open-label trial extensions

1. Wasserstein M, Lachmann R, Hollak C, et al. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results. *Genet Med.* 2022;24(7):1425-1436.
2. Mistry PK, Lukina E, Ben Turkia H, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. *JAMA.* 2015;313(7):695-706.